Heron Therapeutics Inc. (NASDAQ:HRTX) finished Thursday with a subtraction of -$0.07 to close at $1.73, a downside of -3.89 percent. An average of 2,679,500 shares of common stock have been traded in the last five days. There was a gain of $0.1100 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 2,364,920 shares traded, while the 50-day average volume stands at 2,055,584.
HRTX stock has increased by 29.10% in the last month. The company shares reached their 1-month lowest point of $1.2300 on 07/11/23. With the stock rallying to its 52-week high on 01/18/23, shares of the company touched a low of $1.07 and a high of $5.62 in 52 weeks. It has reached a new high 7 times so far this year and lost -30.80% or -$0.7700 in price. In spite of this, the price is down -69.22% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Heron Therapeutics Inc. (HRTX) stock’s beta is 0.96. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.09.
Financial Health
The quick ratio of Heron Therapeutics Inc. for the recent quarter was 1.60, and the current ratio was 2.30, indicating that the company is able to meet its debt obligations. Heron Therapeutics Inc.’s EBITDA margin is -154.51%. Its gross profit as reported stood at $52.8 million compared to revenue of $107.67 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Heron Therapeutics Inc.’s return on assets was -61.10%.
Earnings Surprise
For the recent quarter, Heron Therapeutics Inc. had $32.93 million in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$32.77 million in the quarter, while revenues of -$19.87 million were shrunk -94.96%. Shareholders own equity worth $119.72 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Heron Therapeutics Inc. (HRTX) price momentum. RSI 9-day as of the close on 10 August was 63.06%, suggesting the stock is Neutral, with historical volatility in this time frame at 67.10%.
As of today, HRTX’s price is $1.7100 +6.79% or $0.1100 from its 5-day moving average. HRTX is currently trading +32.06% higher than its 20-day SMA and -25.43% lower than its 100-day SMA. However, the stock’s current price level is +45.38% above the SMA50 and -55.64% below the SMA200.
The stochastic %K and %D were 80.62% and 78.78%, respectively, and the average true range (ATR) was 0.1472. With the 14-day stochastic at 72.00% and the average true range at 0.1414, the RSI (14) stands at 62.09%. The stock has reached 0.0689 on the 9-day MACD Oscillator while the 14-day reading was at 0.1062.
Analyst Ratings
Guggenheim launched coverage on Heron Therapeutics Inc. (NASDAQ: HRTX) in its analyst report released on May 27, 2020. The firm assigned the stock a Buy rating. The consensus rating for Heron Therapeutics Inc. (HRTX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell HRTX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.
What is HRTX’s price target for the next 12 months?
Analysts predict a range of price targets between $5.00 and $10.00, with a median target of $8.00. Taking a look at these predictions, the average price target given by analysts for Heron Therapeutics Inc. (HRTX) stock is $7.75.
